SNSaman Ahmad Nasrollahi

Saman Ahmad Nasrollahi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saman Ahmad Nasrollahi has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preparation and Optimization of Voriconazole Gel 0.25% for Topical Delivery in Terbinafine Resistance Dermatophytosis: In Vitro and Pilot Animal Study

    by Saman Ahmad Nasrollahi, Mahsa Fattahi, Ensieh Lotfali, Atefeh Naeimifar, Fatemeh Amiri, Aliasghar Ghaderi, Pegah Tamimi, Shayan Zamani, Ali Khamesipoor, Alireza Firooz

    Background: There have been several reports of patients with chronic recalcitrant diseases, rare presentations, recurrent relapses, and treatment failure. This study aimed to formulate and evaluate the safety profile of topical voriconazole (VCZ) gel 0.25% for effective drug delivery to the skin as an adjuvant therapy in cases of extensive dermatophytosis. Methods and Materials: VCZ 0.25% topical gel was manufactured by Carbomer, and its characteristics such as pH, viscosity, density, and microbial growth were examined at 40 ± 2°C/75 ± 5% RH for six months. The animals were divided into three groups (2:2:2) randomly. The hair from the back of guinea pigs (test sites: 2 cm 2 ) was shaven, and their skin was scraped slightly using a single‐use scalpel. Afterward, terbinafine drug–resistant Arthroderma benhamiae suspension (50 μL) was inoculated to a 2 cm 2 surface area of the shaven skin. Results: Agar culture of scrapings from the area indicated the infection development. The fabricated VCZ topical gel exhibited acceptable stability. The VCZ 0.25% gel was proved to be an effective treatment in a time‐dependent base, in comparison with terbinafine (1%) as a positive control ( p < 0.05). Furthermore, using gel base VCZ 0.25% reduced the period of full treatment of A. benhamiae infection to five days, compared with the 12‐day complete cure by terbinafine. Conclusion: Results from the present study indicated that gel‐based VCZ could be utilized as topical therapy for dermatophytosis. Due to the increase of drug‐resistant dermatophyte spp., indications of gel base VCZ 0.25% for treating dermatophytosis are believed to increase accordingly.

  • Open Access

    Efficacy and Safety of Oxymetazoline 1% Cream for the Treatment of Mild to Moderate Facial Rosacea

    by Fatemeh Sajdeh, Aniseh Samadi, Atefeh Naeimifar, Taraneh Yazdanparast, Maryam Ahmadi, Fatemeh Amiri, Martin Kassir, Alireza Firooz, Saman Ahmad Nasrollahi

    Introduction: Rosacea is a common skin condition that affects the physical and mental health of the patient. The objective of this study was to evaluate the efficacy and safety of oxymetazoline 1% cream, a specific α1A‐adrenoceptor agonist, for the treatment of mild to moderate facial rosacea.Methods: In phase II of the before–after study, 15 patients with mild to moderate rosacea were enrolled and treated with oxymetazoline 1% cream twice daily for 4 weeks. The clinician's erythema assessment (CEA) and patient's self‐assessment (PSA), as well as the skin biometric parameters (transepidermal water loss, sebum, stratum corneum hydration, temperature, erythema, melanin, and pH), dermal and epidermal thickness and echo‐density, and capillaroscopic pattern were assessed and compared before and after treatment. p‐Value < 0.05 was considered significant.Results: CEA and PSA indexes decreased significantly 2 and 4 weeks after the treatment (p‐value: 0.001). The erythema index also decreased significantly in both 2 weeks (p‐value: 0.001) and 4 weeks (p‐value: 0.001) after the treatment. The capillaroscopic pattern of lesions showed a decrease in telangiectasia and a reddish background of skin. No side effects of treatment were experienced by any of the patients.Conclusion: Oxymetazoline 1% cream was safe and effective in treating mild to moderate facial rosacea. The reduction in the skin's vascularity was also objectively confirmed.


  • Open Access

    Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea

    by Samin Fallah Pakdaman, Aniseh Samadi, Mahsa Fattahi, Atefeh Naeimifar, Fatemeh Amiri Ardehali, Yasaman Ketabi, Saman Ahmad Nasrollahi, Alireza Firooz

    Background & Aim: Rosacea is a chronic inflammatory, multifactorial disease for which combination therapy could be an effective treatment. In this study, we evaluate the effect of the combination therapy of brimonidine 0.33% and ivermectin 1% as a single cream for the treatment of papulopustular rosacea. Method: A stable and appropriate formulation was prepared by adding the aqueous phase to the lipid phase while being stirred. The stability and physicochemical properties of the formulation were evaluated under accelerated conditions. Twelve patients (36–60 years) with mild to moderate papulopustular rosacea and a Demodex count of five or more were treated with the combination of brimonidine 0.33% and ivermectin 1% cream. Clinician's Erythema Assessment (CEA), Patients Self‐Assessment (PSA), skin erythema (ΔE) and lightness (ΔL), and skin biophysical parameters including transepidermal water loss (TEWL), skin hydration, pH, and sebum content, as well as erythema and melanin index and ultrasound parameters, were measured before treatment and 4 and 8 weeks after. Adverse drug reactions were also recorded. Results: CEA and PSA decreased significantly from 3 to 2 after 8 weeks, respectively ( p ‐value = 0.014 for CEA and 0.010 for PSA). ΔE and ΔL, as well as skin erythema index and TEWL improved after 8 weeks of treatment ( p < 0.05). Two patients withdrew from the study in the first week because of local adverse effects; one developed flushing following treatment and left the investigation after 4 weeks and another patient withdrew from the study after 4 weeks due to deciding to become pregnant. Conclusion: Eight‐week treatment with the combination of brimonidine 0.33% and ivermectin 1% was shown to be effective for improvement of erythema and inflammatory lesions in mild to moderate papulopustular rosacea.


  • Open Access

    Safety and Efficacy Assessment of a Cross‐linked Hyaluronic Acid Dermal Filler for Correction of Moderate‐to‐Severe Nasolabial Folds in Skin Types III and IV

    by Taraneh Yazdanparast, Saman Ahmad Nasrollahi, Aniseh Samadi, Hamidreza Kafi, Mansour Nassiri Kashani, Azin Ayatollahi, Alireza Firooz

    Introduction. Hyaluronic acid fillers are widely used to correct nasolabial folds. This treatment provides favorable aesthetic outcomes. The aim of this study was the safety and efficacy evaluation of Lunaphil Ultra intradermal filler for correcting nasolabial folds in the Iranian population with Fitzpatrick skin types III and IV. Methods. In this before and after clinical study, Lunaphil Ultra dermal filler was injected in nasolabial folds of 24 female and 6 male volunteers (mean age: 43.36 and SD: 11.55). Two independent physicians assessed the severity of nasolabial folds before injection and 2, 12, and 24 weeks later, according to the Allergan scale. The volume, depth, and area of both nasolabial folds and the thickness and density of the dermis in the right nasolabial fold were also measured. Adverse events and subject satisfaction were also recorded. Results. One grade or more improvement was detected in 81%, 57%, and 65% of participants at weeks 2, 12, and 24, respectively. The median score for the Allergan scale decreased significantly in all follow‐up visits. The median value of the area of nasolabial folds significantly reduced in all follow‐up visits. Two weeks after injection, dermis density showed a significant increase. The mean score for pain level during the injection was 1.96 out of 10. Adverse events were mild and transient. The median satisfaction scores were 9‐10 out of 10 at different visits. Conclusion. The findings showed that cross‐linked hyaluronic acid dermal filler containing lidocaine could be applied in clinical practice for correction of nasolabial folds in skin types III and IV, with high safety and efficacy. More comprehensive future research could approve these results. This trial is registered with IRCT20150101020514N11.


  • Open Access

    Assessment of the efficacy and tolerability of a topical formulation containing caffeine and Procapil 3% for improvement of male pattern hair loss

    by Aniseh Samadi, Elnaz Rokhsat, Zahra Saffarian, Mehdi Moazzami Goudarzi, Sina Kardeh, Saman Ahmad Nasrollahi, Alireza Firooz


  • Open Access

    Reply to: “Is oral collagen the elixir of youth?”

    by Aniseh Samadi, Saman Ahmad Nasrollahi, Alireza Firooz

    Following letter provides answers and explanations for the correspoundance titled “Is oral collagen the elixir of youth.” They have admitted the strengths of our study and also have raised some questions about it, which we aim to provide answers and explanations.

  • Open Access

    Tolerability and efficacy assessment of an oral collagen supplement for the improvement of biophysical and ultrasonographic parameters of skin in middle eastern consumers

    by Aniseh Samadi, Maryam Movaffaghi, Faegheh Kazemi, Taraneh Yazdanparast, Saman Ahmad Nasrollahi, Alireza Firooz

    Background: Topical skin care products often do not reach the deeper layers of the skin, and oral hydrolyzed collagen is one of the newest and most popular systemic supplementations for skin rejuvenation. However, there are limited information in case of Middle Eastern consumersObjective: The purpose of this study was to evaluate the tolerability and efficacy of an oral collagen supplement for improvement of skin elasticity, hydration, and roughness in Middle Eastern consumers.Methods and Materials: It was a 12‐week, before‐after clinical study, conducted on 20 participants (18 women and 2 men) aged 44.15 ± 5.36 years with skin type III–IV. Skin elasticity parameters (R0, R2, R5, and R7), skin hydration and friction, as well as the thickness and echo density of the dermis, were measured after six and 12 weeks daily intake of the study product, as well as 4 weeks after stopping its use (week 16). Participants' satisfaction was assessed on the basis of their answers to the standard questionnaire, and tolerability of the product was assessed by monitoring the adverse effects.Results: A significant improvement was detected in R2, R5, and skin friction at week 12 (p‐values 0.041, 0.012 and p‐value = 0.03). Moderate overall satisfaction was reported with the treatment, and a few gastrointestinal complications were reported.Conclusion: The study demonstrated that oral collagen peptides could significantly improve the skin elasticity, roughness, and dermis echo density, and they also proved to be safe and well‐tolerated.


  • Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study

    by Atefeh Naeimifar, Saman Ahmad Nasrollahi, Aniseh Samadi, Zeinab Aryanian, Hamid Akbari Javar, Mohammadreza Rouini, Mansour Nassiri Kashani, Alireza Firooz

    Ruxolitinib is a JAK1/2 inhibitor, which inhibits the signal transduction of interferon-gamma, a cytokine implicated in the pathogenesis of atopic dermatitis (AD). In this before-after single group...


  • Designing a Topical Nanoliposomal Formulation of Ruxolitinib Phosphate

    by Atefeh Naeimifar, Saman Ahmad Nasrollahi, Hamid Akbari Javar, Mansoor Nassiri Kashani, Alireza Firooz, Mohamadreza Rouini

    Background: The JAK-STAT pathway has been revealed to play a crucial role in the dysregulation of immune responses in autoimmune skin disorders. Ruxolitinib, a selective inhibitor of JAK1 and JAK2, potently suppresses cytokine signaling. Methods: A topical emulgel containing ruxolitinib nanoliposome (RuxoLip) was prepared by thin film hydration method. Then, its physicochemical characteristics were evaluated at 25±2 ̊C/60±5% RH for 12 months. RuxoLip was assessed based on particle characteristics, Scanning Electron Microscopy (SEM), entrapment efficiency (EE), drug loading (DL), and Differential Scanning Calorimetry (DSC). The pH, density, viscosity, microbial assessment, in vitro drug release, and in vivo tape stripping test were evaluated on the emulgel of RuxoLip. Validating the analysis method was performed by UV spectroscopy. Results: Nanoliposomal preparation was successfully formulated with a good particle size (218±2 nm), an EE of 67% and a DL of 8%. The formulation was stable in a long-term condition. SEM showed that liposomes had a regular spherical surface. Moreover, in vitro drug release and the in vivo tape stripping test revealed good absorption and permeation, respectively. Conclusion: The liposome dosage form is anticipated to be a perfect carrier for the topical drug delivery system of ruxolitinib in autoimmune skin disorders.


  • Caspofungin resistance in clinical Aspergillus flavus isolates

    by Zeynab Yassin, Ensieh Lotfali, Mohammad Rafi Khourgami, Negar Omidi, Azam Fattahi, Saman Ahmad Nasrollahi, Reza Ghasemi